

Statin Therapy for Patients with Cardiovascular Disease (SPC)

HEDIS Tip Sheet MY 2025



Measure definition	Plans(s)	Quality Program(s)	Collection and Reporting
The percentage of males aged 21–75 years and females aged 40–75 years during the measurement year who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the criteria listed below: - Received statin therapy – Members who were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year. - Statin adherence 80% – Members who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period.	Medicaid Medicare	CMS Stars Ratings NCQA Accreditation NCQA Health Plan Ratings	Administrative Claim/Encounter Data Pharmacy Data

Note: Only the “Received Statin Therapy” component is required to be compliant for the SPC Medicare Star Measure.

Best practices for quality care

- Educate members on the importance of statin adherence and potential side effects, advising them to contact you if they experience muscle pain or weakness. Adjust statin dosage or frequency if needed or consider switching to a different statin medication to improve tolerance.
- Document any side effects from statin therapy and determine if the symptom(s) qualifies as an exclusion.
- Emphasize statin therapy alongside lifestyle changes, such as exercise (even at home) and a culturally appropriate healthy diet.
- Encourage members to follow through with prescribed 90-day prescriptions or mail orders to minimize barriers to obtaining medications on time.
- Encourage members to use their insurance benefits for statin prescriptions and provide directives to pharmacies to run prescriptions through insurance for proper gap closure.
- Prescribe the lowest cost statin medications to avoid financial burdens. Using discount cards without a pharmacy claim being filed will not lead to gap closure.
- Reach out to patients regularly for follow-up visits and discuss the importance of statin medication adherence.

Quality score improvement tips

- Ensure the prescription details (drug name, strength, dose, route, and date) are accurately documented.

Exclusions

- Pregnancy-related conditions, including diagnosis of pregnancy, IVF or clomiphene use during the measurement year or prior year.
- End-stage renal disease, dialysis or cirrhosis during the measurement year or prior year.
- Myalgia, myositis, myopathy or rhabdomyolysis during the measurement year. Myalgia or rhabdomyolysis caused by a statin any time during the member's history through December 31 of the measurement year.
- Members who used hospice services or elected to use a hospice benefit anytime during the measurement year.
- Members who died any time during the measurement year.
- Members who received palliative care or had an encounter for palliative care any time during the measurement year.
- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
 - o Enrolled in an institutional SNP (I-SNP) any time during the measurement year.
 - o Living long term in an institution any time during the measurement year.
- Members 66 years of age as of December 31 of the measurement year, with frailty and advance illness. Members must meet both frailty and advance illness criteria to be excluded:
 - o Frailty – At least two indications of frailty with different dates of service any time during the measurement year.
 - o Advanced illness – Must have one of the following during the measurement year or the year prior:
 - Advanced illness on at least two different dates of service.
 - Dispensed dementia medication (Donepezil, Donepezil-memantine, galantamine, rivastigmine or memantine).

High- and Moderate-Intensity Statin Medications

Description	Prescription
High-intensity statin therapy	• Atorvastatin 40-80 mg
High-intensity statin therapy	• Amlodipine-atorvastatin 40-80 mg
High-intensity statin therapy	• Rosuvastatin 20-40 mg
High-intensity statin therapy	• Simvastatin 80 mg
High-intensity statin therapy	• Ezetimibe-simvastatin 80 mg
Moderate-intensity statin therapy	• Atorvastatin 10-20 mg
Moderate-intensity statin therapy	• Amlodipine-atorvastatin 10-20 mg
Moderate-intensity statin therapy	• Rosuvastatin 5-10 mg
Moderate-intensity statin therapy	• Simvastatin 20-40 mg

Moderate-intensity statin therapy	• Ezetimibe-simvastatin 20-40 mg
Moderate-intensity statin therapy	• Pravastatin 40-80 mg
Moderate-intensity statin therapy	• Lovastatin 40 mg
Moderate-intensity statin therapy	• Fluvastatin 40-80 mg
Moderate-intensity statin therapy	• Pitavastatin 1-4 mg

How WellSense can help

HEDIS tip sheets are designed to help WellSense providers improve and report the quality of care delivered to WellSense members across key metrics.

If you have questions around HEDIS documentation and quality measures, please email the Quality Team at WS_Quality_Dept@wellsense.org.